RTTNews | Sep 16, 2020 09:58AM EDT

09:57 Wednesday, September 16, 2020 (RTTNews.com) - Shares of Arrowhead Pharmaceuticals Inc. (ARWR) are currently gaining over 25% on Wednesday morning after the company reported positive interim results from a mid-stage trial of treatment for rare genetic liver disease.

ARWR is currently trading at $42.29, up $8.49 or 25.12%, on the Nasdaq.

Arrowhead announced positive interim 24-week liver biopsy results in four subjects from AROAAT2002.

AROAAT2002 is a phase 2 study of ARO-AAT, the company's second generation investigational RNA interference therapeutic being developed as a treatment for the rare genetic liver disease associated with alpha-1 antitrypsin deficiency.

The company said, "the results show clear evidence of a meaningful pharmacodynamic effect by ARO-AAT, leading to improvements in relevant biomarkers, including substantial reductions in intra-hepatic mutant AAT protein, both Z-AAT monomer and Z-AAT polymer; improvements in liver stiffness based on FibroScan; and, a decrease in alanine aminotransferase and gamma-glutamyl transferase, both serum biomarkers of liver injury."

Read the original article on RTTNews ( https://www.rttnews.com/3129114/stock-alert-arrowhead-jumps-25-on-positive-results-for-rare-genetic-liver-disease-treatment.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved